Pfizer's hot start to the new year continues with licensing deal for mysterious biotech's solid tumor bispecifics
Pfizer has been quite busy as the new year kicked off, and Tuesday the Big Pharma struck yet another deal — this time with a little-known California biotech.
It’s a partnership worth more than $1 billion when all is said and done, with Pfizer enlisting the aid of Dren Bio in a bispecific antibody collaboration. Dren gets $25 million upfront to develop one of its candidates toward two solid tumor targets selected by Pfizer, and Pfizer has the option to nominate more targets in the future, per a press release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.